skip to content »

Neurology

Houston, Texas

The Cullen Building at Baylor College of Medicine.
Department of Neurology
not shown on screen

Poster and Platform Presentations by ADMDC Members

Click on the Expand plus sign sign to list the poster and platform presentations by year. Then click on the link to view that presentation.

Time Line

Expand All

2014

Collapse All | Expand All

 

2013

Collapse All | Expand All

 

    2013 Alzheimer's Association International Conference (AAIC)
    Boston, Mass. (July 13-18, 2013)

    State University of New York (SUNY)
    Upstate Medical Center, Neurology Grand Rounds in Syracuse, N.Y. (June 2013)

    • An update on Alzheimer's disease.
      [Oral Presentation]

      Sood A

    State University of New York (SUNY)
    Upstate Medical University Annual Regional Stroke Conference in East Syracuse, N.Y. (April 27, 2013)

    • Endovascular therapy of acute ischemic stroke and the role of intra-arterial vasodilators.

      Sangha RS, Sood A, Patel K, Latorre JG, El-Zammar Z, Sangha RS

    • Intra-arterial tPA in basilar artery stenosis within three hour window with high INR.
      [Oral Presentation]

      Sood A

    American Academy of Neurology (AAN)
    65th Annual Meeting in San Diego, Calif. (March 16-23, 2013)

    International Neuropsychological Society (INS)
    41st Annual Meeting in Montreal, Waikoloa, Hawaii (Feb. 6-9, 2013)

    • A simple method for enhancing prediction of longitudinal decline in instrumental activities of daily living in Alzheimer's patients.

      Grabyan JM, Massman PJ, Alverson W, Doody RS

    • Improving predictive validity of the Clinical Dementia Rating Scale for functional outcomes.

      Lowe DA, Balsis S, Miller T, Benge JF, Doody RS.

2012

Collapse All | Expand All

 

    National Academy of Neuropsychology (NAN)
    32nd Annual Meeting in Nashville, Tenn. (Nov. 7-10, 2012)

    • Mexican American normative references on tasks of memory and language: The Texas Mexican American normative studies.

      Edwards M, Balldin V, Hall J, Strutt A, Pavlik V, Marquez de la Plata C, et al.

    • Normative data for Mexican American on tasks of executive and physiometric functions: The Texas Mexican American normative studies.

      Hall J, Edwards M, Balldin V, Strutt A, Pavlik V, Marquez de la Plata C, et al.

    • Normative performance on the RBANS in a multi-ethnic bilingual cohort: The Texas Mexican American normative studies.

      Hobson Balldin V, Menon C, Younes S, Hall J, Strutt A, Pavlik V, et al.

    American Neurological Association (ANA)
    137th Annual Meeting in Boston, Mass. (Oct. 7-9, 2012)

    • Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease.
      [Platform Presentation]

      Szigeti K, Lal D, Li Y, Doody RS, Yan L

    Alzheimer's Association International Conference (AAIC)
    Annual Meeting in Vancouver, British Columbia, Canada (July 14-19, 2012)

    International Neuropsychological Society (INS)
    40th Annual Meeting in Montreal, Quebec, Canada (Feb. 15-18, 2012)

<2011

Collapse All | Expand All

 

    2011 International Conference on Alzheimer's Disease (ICAD)
    Paris, France (July 16-21, 2011)

    • Serum granulocyte colony stimulating factor and Alzheimer's disease.

      Barber R, O'Bryant S, Reisch J, Doody R, Fairchild T, Adams P, et al.

    • The impact of depression on cognition varies by APOE4 status.

      Dentino A, Hall J, Barber R, Doody R, Royall D, O'Bryant S

    • Biomarkers associated with cardiovascular risk in the Texas Alzheimer's Disease Research and Care Consortium (TARCC) Cohort: LpPla2 and homocysteine.

      Doody R, Chan W, Ballantyne C, Pavlik V, Barber R, O'Bryant S, et al.

    • Inflammatory biomarkers in the Texas Alzheimer's Research and Care Consortium (TARCC) Cohort.

      Doody R, Chan W, Barber R, Ballantyne C, Pavlik V, O'Bryant S, et al.

    • Plasma sphingomyelin is associated with cognitive progression in Alzheimer's disease.

      Mielke M, Haughey N, Bandaru VVR, Weinberg D, Zaidi N, Pavlik V, et al.

    • Refinement and expansion of the Texas Alzheimer's research consortium serum-based diagnostic algorithm for Alzheimer's disease.

      O'Bryant S, Xiao G, Barber R, Hall J, Doody R, Reisch J, et al.

    • A serum protein-based algorithm for the detection of Alzheimer's disease.

      O'Bryant S, Xiao G, Robert B, Hall J, Doody R, Reisch J, et al.

    • Racial/ethnic group differences in the association of APOE ε4 genotype and visuospatial test performance in a non-demented sample.

      Pavlik V, Massman P, Rustveld L, Doody R

    • Factors that influence survival in Alzheimer's patients.

      Rountree S, Chan W, Pavlik V, Darby E, Doody R

    • The cognitive correlates of functional status: a new approach to dementia.

      Royall DR, Doody R, Barber R, Palmer R, O'Bryant S, Reisch J, et al.

    • Genome-wide association scan replication for biomarker endophenotypes of Alzheimer's disease.

      Wilhelmsen K, Chasse S, Griffin N, Diaz-Arrastia R, Barber R, Royall D, et al.

    • Developing and validating of diagnostic algorithm for Alzheimer's disease.

      Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, et al.

    American Academy of Neurology (AAN)
    63rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)

    International Neuropsychological Society (INS)
    39th Annual Meeting in Boston, Mass. (Feb. 2-5, 2011)

    Loyola University Medical Center, Stritch School of Medicine
    Grand Rounds in Maywood, Ill. (December 2010)

    • A tale of spinacia oleracea.
      [Oral Presentation]

      Sood A

    2010 International Conference on Alzheimer's Disease (ICAD)
    Honolulu, Hawaii (July 10-15, 2010)

    American Academy of Neurology (AAN)
    62nd Annual Meeting in Toronto, Canada (April 10-17, 2010)

    Society for Neuroscience (SFN)
    39th Annual Meeting in Chicago, Ill. (Oct. 17-21, 2009)

    • Plasticity of hippocampo-cortical network connectivity induced by midline thalamic (n. Reuniens) stimulation in the rat.

      Viana Di Prisco G, Albo Z, Vertes RP

    American Academy of Neurology (AAN)
    61st Annual Meeting in Seattle, Wash. (April 25 - May 2, 2009)

    International Neuropsychological Society (INS)
    37th Annual Meeting in Atlanta, Ga. (Feb. 11-14, 2009)

    Society for Neuroscience (SFN)
    38th Annual Meeting in Washington, DC (Nov. 15-19, 2008)

    • Alzheimer's disease as descent into randomness: Evidence from category fluency testing.

      Lerner AJ, Albo Z, Messer J, Singh T, Woyczynski W

    2008 International Conference on Alzheimer's Disease (ICAD)
    Chicago, Ill. (July 26-31, 2008)

    American Academy of Neurology (AAN)
    60th Annual Meeting in Chicago, Ill. (April 12-19, 2008)

    American Neurological Association (ANA)
    132nd Annual Meeting in Washington, DC (Oct. 7-10, 2007)

    2nd International Frontotemporal Dementia in ALS Research Conference
    London, Ontario Canada (June 10-13, 2007)

    Alzheimer's Association International Conference (AAIC)
    Washington, DC (June 9-12, 2007)

    Movement Disorder Society (MDS)
    11th International Congress of Parkinson's Disease and Movement Disorders in Istanbul, Turkey (June 3-7, 2007)

    Medical College of Georgia
    Pharmacology and Toxicology Annual Symposium in Augusta, Ga. (May 2007)

    • Cytoprotective and cognitive enhancing properties of JWB 1-84-1.
      [Oral Presentation]

      Sood A

    American Academy of Neurology (AAN)
    59th Annual Meeting in Boston, Mass. (April 28 - May 5, 2007)

    • Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study.

      Doody R, Gavrilova S, Sano M, Thomas R, Aisen P, Seely L, et al.

    8th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
    Salzburg, Austria (March 14-18, 2007)

    • Design and baseline data for a study of Lipitor's effect in Alzheimer's disease (LEADe).

      Feldman H, Sparks L, Doody R, Kivipelto M, Jones R, Sovel M, et al.

    Southeastern Pharmacology Society (SEPS)
    27th Annual Meeting in Oxford, Mich. (Nov. 5-7, 2006)

    • Effect of JWB1-84-1, a novel analog of choline, on delayed matching accuracy by aged rhesus monkeys and cognitive improvement in transgenic mouse model of Alzheimer's disease.

      Sood A, Webster S, Beach J, Buccafusco J

    Society for Neuroscience (SFN)
    36th Annual Meetingin Atlanta, Ga. (Oct. 14-18, 2006)

    • Cytotoxic effects of abeta42, rage, and a synthetic abeta42-rage complex in PC-12 cells.

      Buccafusco J, Mruthinti S, Capito N, Sood A

    • Effect of JWB 1-84-1, a novel analog of choline, on delayed matching accuracy by aged rhesus monkeys.

      Sood A, Webster S, Beach J, Buccafusco J

    10th International Conference on Alzheimer's Disease and Related Disorders
    Madrid, Spain (July 15-20, 2006)

    Medical College of Georgia
    Pharmacology and Toxicology Annual Symposium in Augusta, Ga. (May 2006)

    • Novel choline analogs offer cytoprotection against growth factor withdrawal in differentiated PC-12 cells.
      [Oral Presentation]

      Sood A

    American Academy of Neurology (AAN)
    58th Annual Meeting in San Diego, Calif. (April 1-8, 2006)

    Medical College of Georgia
    Graduate Research Day in Augusta, Ga. (March 2006)

    • Novel choline analogs offer cytoprotection against growth factor withdrawal in differentiated PC-12 cells.

      Sood A, Webster S, Mruthinti S, Buccafusco J

    International Neuropsychological Society (INS)
    34th Annual Meeting in Boston, Mass. (Feb. 1-4, 2006)

    Society for Neuroscience (SFN)
    35th Annual Meeting in Washington, DC (Nov. 12-16, 2005)

    • Evidence for autoimmunity in Alzheimer's disease: Man, mouse, and monkey.

      Buccafusco J, Sood A, Mruthinti S

    • Cytoprotective properties of novel choline analogs.

      Sood A, Webster S, Mruthinti S, Beach J, Puppali M, Doad G, et al.

    American Neurological Association (ANA)
    130th Annual Meeting in San Diego, Calif. (Sept. 25-28, 2005)

    • Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.

      Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM

    2nd Alzheimer's Association International Conference (AAIC)
    Washington, DC (June 9-12, 2005)

    • Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.

      Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM

    • Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis.

      Thal LJ, Thomas RG, Grundman M, Bennett DA, Doody RS, Ferris SH, et al.

    Medical College of Georgia
    Pharmacology and Toxicology Annual Symposium in Augusta, Ga. (May 2005)

    • Cytoprotective properties of novel choline analogs.
      [Oral Presentation]

      Sood A

    Association for Research in Vision and Ophthalmology (ARVO)
    2005 Annual Meeting in Fort Lauderdale, Fla. (May 1-5, 2005)

    • Superior limbic keratoconjunctivitis in chronic ocular graft vs. Host disease.

      Kim SK, Couriel D, Ghosh S, Khaleeq A, Pflugfelders SC

    American Academy of Neurology (AAN)
    57th Annual Meeting in Miami Beach, Fla. (April 9-16, 2005)

    Experimental Biology
    2005 Annual Meeting in San Diego, Calif. (April 2-6, 2005)

    • The behavioral phenotype of a transgenic mouse model of Alzheimer's disease and the presence of Alzheimer's-related autoimmune markers.

      Sood A, Buccafusco J, Terry A

    Medical College of Georgia
    Graduate Research Day in Augusta, Ga. (March 2005)

    • Amyloid-related autoimmunity and the behavioral phenotype of a transgenic mouse model of Alzheimer's disease.

      Sood A, Mruthinti S, Buccafusco J, Terry A

    European Federation of Neurological Societies (EFNS)
    8th Congress in Paris, France (Sept. 4-7, 2004)

    • Donepezil is safe and well-tolerated in AD patients at doses of up to 20 mg/day.

      Schindler R, Corey-Bloom J, Doody R, Zhang R, Leni JR, Li H

    • Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.

      Wirth Y, Doody RS, Schmitt FA, Mobius HJ, Stoffler A

    9th International Conference on Alzheimer's Disease and Related Disorders
    Philadelphia, Penn. (July 17-22, 2004)

    • Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits.

      Doody R, Pratt R, Posner H, Kumar D

    • Longitudinal analysis of the Alzheimer's Disease assessment scale in a large cohort of probable AD patients.

      Massman P, Doody R

    • Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary.

      Tariot P, Doody R, Peskind E, Winblad B, Reisberg B, Stoffler A, et al.

    • Functional benefits of memantine treatment for patients with moderate to severe Alzhemier's disease.

      Wirth Y, Doody RS, Schmitt FA, Mobius HJ

    XXIVth Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress
    Paris, France (June 20-24, 2004)

    • Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease.

      Wirth Y, Doody R, Schmitt F, Mobius HJ, Stoffler A

    Medical College of Georgia
    Lecture, STAR students in Augusta, Ga. (June 2004)

    • Drug discovery for neurodegenerative diseases.
      [Oral Presentation]

      Sood A

    Medical College of Georgia
    Pharmacology and Toxicology Annual Symposium in Augusta, Ga. (May 2004)

    • Novel choline analogs as neuroprotective and cognitive enhancing drugs.
      [Oral Presentation]

      Sood A

    Medical College of Georgia
    Graduate Research Day in Augusta, Ga. (March 2004)

    • Transport of choline and its analogs.

      Sood A, Buccafusco J

    Society for Neuroscience (SFN)
    33rd Annual Meeting in New Orleans, La. (Nov. 8-12, 2003)

    • Anterior thalamus interaction with the retrosplenial cortex in the anaesthetized rat.

      Albo Z, Ding M, Vertes RP, Viana Di Prisco G

    • Characterization of choline transport in differentiated PC-12 cells.

      Sood A, Buccafusco J, Goldstein B

    International Brain Research Organisation (IBRO)
    6th World Congress on Neuroscience in Prague, Czech Republic (July 10-15, 2003)

    • Coherence analysis of anterior thalamic unit firing with retrosplenial cortical and hippocampal theta rhythm.

      Albo Z, Viana Di Prisco G, Ding M, Vertes RP

    Medical College of Georgia
    Pharmacology and Toxicology Annual Symposium in Augusta, Ga. (May 2003)

    • Cytoprotection and choline analogs.
      [Oral Presentation]

      Sood A

    American Academy of Neurology (AAN)
    55th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003)

    • Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: A comparison of Alzheimer's disease versus vascular dementia.

      Doody RS, Pratt RD, Perdomo CA, the Donepezil 307 and 308 vaD Study Groups

    • Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease.

      Ferris SH, Schmitt FA, Doody RS, Moebius H-J, Stoeffler A, Reisberg BJ

    8th International Conference on Alzheimer's Disease and Related Disorders
    Stockholm, Sweden (July 20-25, 2002)

    • How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses?

      Clark C, Eubank D, Peskind E, Galasko D, Morris J, McKeel D, et al.

    • Pathogenesis and treatment strategies for selected therapies under development.

      Doody RS

    • Long term treatment with the NMDA antagonist memantine: results of a 24-week, open label extension study in moderately severe to severe Alzheimer's disease.

      Reisberg B, Mobius H, Stoffler A, Schmitt F, Doody R, Ferris S

    World Federation of Neurology (WFN)
    Research Group on Neuroepidemiology. Regional North American Annual Meeting in Denver, Colo. (April 19, 2002)

    • Survival in patients with dementia from a large multi ethnic population.

      Waring S, Doody RS

    International Neuropsychological Society (INS)
    30th Annual Meeting in Toronto, Canada (Feb. 13-16, 2002)

    • Growth curve analysis of decline in instrumental activities of daily living in AD patients.

      Davis R, Atchison T, Massman P, Doody R

    • Measurement invariance of theWAIS-R in AD among patients at higher versus lower levels of dementia severity.

      Davis R, Massman P, Doody R

    • WAIS-R factor structure in AD: Comparison of alternative models and assessment of generalizability.

      Davis R, Massman P, Doody R

    Society for Neuroscience (SFN)
    31th Annual Meeting in San Diego, Calif. (Nov. 10-15, 2001)

    • A study of neural interactions within the limbic system using partial coherence and direct transfer functions analysis.

      Albo Z, Viana Di Prisco G, Truccolo W, Vertes RP, Ding M

    World Federation of Neurology (WFN)
    Research Group on Neuroepidemiology. Regional North American Annual Meeting in Philadelphia, Penn. (May 9, 2001)

    • Racial differences among patients with Alzheimer's disease from a large multi ethnic population.

      Waring S, Doody RS

    American Academy of Neurology (AAN)
    53rd Annual Meeting in Philadelphia, Penn. (May 5-11, 2001)

    • The cognitive benefits of galantamine are sustained for at least 24 months: Results of a long-term extension trial in Alzheimer's disease.

      Doody RS, Kershaw P

    Society for Neuroscience (SFN)
    30th Annual Meeting in New Orleans, La. (Nov. 4-9, 2000)

    • Dynamical theta resonance between anterior thalamus and retrosplenial cortex in the anesthetized rat.

      Albo Z, Viana Di Prisco G, Vertes RP

    7th International Conference on Alzheimer's Disease and Related Disorders
    Washington, DC (July 9-18, 2000)

    • Cholinesterase inhibitors: Benefits and limitations.

      Doody RS

    American Academy of Neurology (AAN)
    52nd Annual Meeting in San Diego, Calif. (April 29 - May 6, 2000)

    • Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1-year placebo-controlled functional survival study.

      Mohs R, Doody R, Morris J, Ieni J, Perdomo C, Pratt R

    • Profoundly advanced Alzheimer's disease: Patient characteristics, functional status, disease progression, and care burden.

      Sumaira R, Doody R, Lai EC

    American Society of Consultant Pharmacists (ASCP)
    30th Annual Meeting in St. Loius, Mo. (Nov. 10-13, 1999)

    • Uninterrupted long-term donepezil treatment results in optimal efficacy with retained safety.

      Doody R, Geldmacher DS, Pratt RD, Perdoma CA

    Society for Neuroscience (SFN)
    29th Annual Meeting in Miami Beach, Fla. (Oct. 23-28, 1999)

    • Re-entrant theta activity in Papez circuit: Role of the anterior ventral nucleus of the thalamus.

      Albo Z, Viana Di Prisco G, Vertes RP

    • Patterns of neuronal activity in the median raphe during hippocampal theta rhythm in the anesthetized rat.

      Viana Di Prisco G, Albo Z, Vertes RP

    European College of Neuropsychopharmacology (ECNP)
    12th Congress in London, UK (Sept. 21-25, 1999)

    • Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year placebo-controlled attrition study.

      Mohs R, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, et al.

    European Neurological Society (ENS)
    9th Annual Meeting in Milan, Italy (June 5-9, 1999)

    • Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration.

      Doody RS, Geldmacher DS, Pratt RD, Perdomo CA

    American Academy of Neurology (AAN)
    51st Annual Meeting in Toronto, Canada (April 17-24, 1999)

    • Does ApoE4 correlate with MRI changes in Alzheimer's disease?

      Azher S, Doody RS, Haykal H, Dunn JK, Liao T-Y

    • Clinical benefits of donepezil: Results from a long-term phase III extension trial.

      Doody RS, Pratt R, Perdomo C

    European College of Neuropsychopharmacology (ECNP)
    11th Congress in Paris, France (Oct. 31 - Nov. 4, 1998)

    • Donepezil improves cognition and global function in Alzheimer's disease: Results from U.S. and multinational phase III clinical trials.

      Petit H, Doody RS, Pratt R

    6th International Conference on Alzheimer's Disease and Related Disorders
    Amsterdam, The Netherlands (July 18-23, 1998)

    • Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients.

      Doody RS, Clark C, Farlow M, Foster N, Gonzales N, Liao J, et al.

    • The presence of APO E4 does not influence rate of decline in Alzheimer's disease.

      Kataki M, Doody RS, Liao J, Sims J

    Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
    Geneva, Switzerland (April 15-18, 1998)

    • Current therapeutic standards in the treatment of Alzheimer's disease.

      Doody RS

    • Research outcome measures in Alzheimer's disease: Statistical significance, effect size and responder analysis - How do they translate to clinical relevance?

      Rogers S, Mohs R, Friedhoff L, Doody RS

    Society for Neuroscience (SFN)
    27th Annual Meeting in New Orleans, La. (Oct. 25-30, 1997)

    • Theta-rhythmic neuronal activity in anterior thalamic nuclei of the rat.

      Kirk IJ, Albo Z, Vertes RP

    American Academy of Neurology (AAN)
    49th Annual Meeting in Boston, Mass. (April 15-17, 1997)

    • Outcome measures in dementia trials-video CIBIC validity and reliability.

      Quinn JF, Benson DF, Clark C, Doody RS, Jagust W, Knopman D, et al.

    American College of Neuropsychopharmacology (ACNP)
    35th Annual Meeting in San Juan, Puerto Rico (Dec. 9-13, 1996)

    • Donepezil HCI (E2020) improves cognitive and global function in patients with mild and moderately severe Alzheimer's disease: Results of a 15-week phase III study.

      Rogers SL, Doody RS, Mohs RC, Friedhoff LT

    Society for Neuroscience (SFN)
    26th Annual Meeting in Washington, DC (Nov. 16-21, 1996)

    • Long lasting changes in cortical excitatory amino acid receptor levels and dopamine-induced behavior after neonatal excitotoxic lesions of the ventral hippocampus in rats.

      Albo Z, Flores G, Barbeau D, Quirion R, Srivastava LK

    International Behavioral Neuroscience Society (ISBN)
    5th Annual Meeting in Cancun, Mexico (May 2-5, 1996)

    • Prevalence of uncontrolled hypertension in a population of Alzheimer's patients.

      Kashani A, Doody RS, Wayner MJ, Phelix CF

    American Academy of Neurology (AAN)
    48th Annual Meeting in San Francisco, Calif. (March 23-30, 1996)

    • Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment.

      Grundman M, Petersen R, Morris J, Ferris S, Sano M, Farlow M, et al.

    • E-2020 Produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial.

      Rogers S, Doody RS, Mohs R, Friedhoff L

    • Pharmacologic evidence for autonomic psudomotor dysfunction in patients with Alzheimer's disease.

      Sabbagh N, Smith RG, Lynn P, Doody RS, Appel SH, Killian JH

    International Neuropsychological Society (INS)
    24th Annual Meeting in Chicago, Ill. (Feb. 14-17, 1996)

    • Reliability and validity of a new clinical global rating scale for Alzheimer's clinical trials.

      Olin J, Clark C, Doody RS, Schmitt F, Ferris S, Morris J, et al.

    Gerontological Society of America (GSA)
    50th Annual Meeting in Los Angeles, Calif. (Nov. 15-19, 1995)

    • A new clinical global rating scale for Alzheimer's clinical trials.

      Olin J, Schneider L, Clark C, Doody RS, Ferris S, Morris J, et al.

    Society for Neuroscience (SFN)
    25th Annual Meeting in San Diego, Calif. (Nov. 11-16, 1995)

    • Cortical NMDA receptor levels are increased in adult rats following neonatal excitotoxic lesions of the ventral hippocampus.

      Albo Z, Flores G, Barbeau D, Quirion R, Srivastava LK

    American Neuropsychiatric Association (ANPA)
    7th Annual Meeting in Pittsburgh, Penn. (Oct. 12-15, 1995)

    • Estrogen and psychomotor performance.

      Doody RS, Young R, Lynn P, Cooke N, Rosenfield JE

    American Academy of Neurology (AAN)
    47th Annual Meeting in Seattle, Wash. (May 6-13, 1995)

    • A calculated measure to predict rate of progression in Alzheimer's disease.

      Doody RS, Lynn P, Massman PJ

    International Neuropsychological Society (INS)
    23rd Annual Meeting in Seattle, Wash. (Feb. 8-11, 1995)

    • Sex differences involving naming in Alzheimer's disease: Stronger relationships with left hemisphere functioning in men.

      Massman PJ, Doody RS

    American Academy of Neurology (AAN)
    46th Annual Meeting in Washington, DC (May 1-7, 1994)

    • Psychometric profiles of Alzheimer's disease (AD) with/without white matter changes compared to subcortical ischemic vascular dementia (IVD).

      Doody RS, Massman PJ, Nance ML

    • Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs.

      Massman PJ, Kreiter KT, Jankovic J, Doody RS

    International Neuropsychological Society (INS)
    22nd Annual Meeting in Cincinnati, Ohio (Feb. 2-5, 1994)

    • Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease.

      Massman PJ, Kreiter KT, Jankovic J, Doody RS

    American Neurological Association (ANA)
    118th Annual Meeting in Boston, Mass. (Oct. 18-20, 1993)

    • Dysfluency in the speech of AD patients.

      Doody RS, Massman P

    • Literacy and cognition in northern Thailand.

      Doody RS, Welsh K

    American Society of Human Genetics (ASHG)
    43rd Annual Meeting in New Orleans, La. (Oct. 5-9, 1993)

    • Simulation analysis of a large British pedigree segregating a newly characterized autosomal dominant language disorder: Familial developmental dysphasia.

      Dunn W, Doody RS, Gopnik M, Ashizawa T

    American Psychiatric Association (APA)
    146th Annual Meeting in San Francisco, Calif. (May 22-27, 1993)

    • Neuroimaging findings and clinical variables associated with psychosis in Alzheimer's disease.

      Kotrla K, Chacko R, Jhingran S, Doody RS

    International Neuropsychological Society (INS)
    21st Annual Meeting in Galveston , Texas (Feb. 24-27, 1993)

    • Correlates of asymmetric motor speed in Alzheimer's disease.

      Massman P, Doody RS

    National Academy of Neuropsychology (NAN)
    12th Annual Meeting in Pittsburgh, Penn. (Nov. 5-7, 1992)

    • Neuropsychological correlates of apraxia in Alzheimer's disease patients.

      Massman P, Doody RS

    American Anthropological Association (AAA)
    90th Annual Meeting in Chicago, Ill. (Nov. 20-24, 1991)

    American Neurological Association (ANA)
    116th Annual Meeting in Seattle, Wash. (Sept. 28 - Oct. 2, 1991)

    • Single photon emission computerized tomography (SPECT) in Alzheimer's disease and multiple-infarct dementia.

      Doody RS, Strittmatter WJ, Jhingran S

    • Establishing the limits of the mini-mental state: MMS "subtests" versus a full neuropsychological battery.

      Feher E, Mahurin R, Doody RS, Cooke N, Simms J, Pirozzolo F

    • Positive and negative psychiatric symptoms in Alzheimer's disease.

      Mahurin R, Feher E, Doody RS, Inbody S

    American Academy of Neurology (AAN)
    43rd Annual Meeting in Boston, Mass. (April 21-27, 1991)

    • The alien hand and related signs.

      Doody RS, Jankovic J

    American Anthropological Association (AAA)
    89th Annual Meeting in New Orleans, La. (Nov. 27 - Dec. 2, 1990)

    American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
    37th Annual Meeting in Chicago, Ill. (Sept. 7-8, 1990)

    • Recurrent posterior-type aphasia associated with a seizure focus.

      Doody RS, Hrachovy RA

    American Academy of Neurology (AAN)
    42nd Annual Meeting in Miami, Fla. (April 2-4, 1990)

    • Progressive nonfluent aphasia.

      Feher E, Doody RS, Whitehead J, Priozzolo F

    American College of Cardiology (ACC)
    31st Annual Scientific Session in Atlanta, Ga. (April 25-29, 1982)

    • Effects of stress management and dietary changes in treating ischemic heart disease.

      Ornish DM, Scherwitz LW, Doody RS, et al.

E-mail this page to a friend